Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Bullish option flow detected in Viking Therapeutics (VKTX) with 8,905 calls trading, 2x expected, and implied vol increasing over 15 points to ...

Shares of NASDAQ:VKTX opened at $26.52 on Tuesday. Viking Therapeutics has a 12-month low of $24.41 and a 12-month high of $89.10. The business has a 50 day moving average of $32.88 and a two ...

Do they really matter, though? Let's take a look at what these Wall Street heavyweights have to say about Viking Therapeutics, Inc. (VKTX) before we discuss the reliability of brokerage ...